Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Current Assets (2019 - 2025)

Silence Therapeutics' Current Assets history spans 7 years, with the latest figure at $118.7 million for Q4 2025.

  • For Q4 2025, Current Assets fell 36.67% year-over-year to $118.7 million; the TTM value through Dec 2025 reached $118.7 million, down 36.67%, while the annual FY2025 figure was $118.7 million, 36.67% down from the prior year.
  • Current Assets for Q4 2025 was $118.7 million at Silence Therapeutics, down from $133.6 million in the prior quarter.
  • Across five years, Current Assets topped out at $187.4 million in Q4 2024 and bottomed at $100.6 million in Q4 2023.
  • The 5-year median for Current Assets is $126.1 million (2025), against an average of $136.0 million.
  • The largest annual shift saw Current Assets soared 86.32% in 2024 before it crashed 36.67% in 2025.
  • A 5-year view of Current Assets shows it stood at $116.4 million in 2021, then decreased by 2.55% to $113.4 million in 2022, then decreased by 11.33% to $100.6 million in 2023, then skyrocketed by 86.32% to $187.4 million in 2024, then plummeted by 36.67% to $118.7 million in 2025.
  • Per Business Quant, the three most recent readings for SLN's Current Assets are $118.7 million (Q4 2025), $133.6 million (Q3 2025), and $148.6 million (Q2 2025).